C-fos蛋白的表达与鼻咽癌化疗敏感性和预后的关系

刘彦婷; 赵飞鹏; 苗洪宾; 傅少志; 周珊; 张旭戈; 覃纲

doi:10.13201/j.issn.1001-1781.2018.09.011

C-fos蛋白的表达与鼻咽癌化疗敏感性和预后的关系

- 1. 西南医科大学附属医院耳鼻咽喉头颈外科(四川泸州, 646000);
- 2. 西南医科大学附属医院肿瘤科
基金项目:
国家自然科学基金项目 (No:81602570, No:81773529)

四川省应用基础研究项目 (No:2017JY0109)

详细信息

通讯作者: 覃纲, E-mail:qin-lzm@163.com

中图分类号: R739.62

收稿日期: 2018-03-13

Expression of C-fos in nasopharyngeal carcinoma and the relationship with chemosensitivity and prognosis

- 1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China;
- 2 Department of Oncology, Affiliated Hospital of Southwest Medical University

More Information

Corresponding author: QIN Gang, E-mail: qin-lzm@163.com

Received Date: 13 March 2018

摘要

摘要: 目的: 探讨C-fos蛋白在鼻咽癌(NPC)组织中的表达,并分析其与肿瘤临床病理因素、化疗敏感性及预后的关系。方法: 使用免疫组织化学技术检测75例NPC和30例鼻咽部慢性炎组织中C-fos 的表达;采用ATP生物荧光抗癌药物敏感性检测技术检测75例NPC组织细胞对8种化疗药物的体外敏感性;分析C-fos表达与NPC临床病理因素、化疗敏感性及预后的关系。结果: C-fos蛋白在NPC中的表达显著高于慢性炎组织(P<0.001);C-fos蛋白的表达量与患者年龄、性别、病理类型、TNM分期及临床分期均差异无统计学意义(P>0.05);NPC对8种化疗药物普遍敏感且敏感性不同(P<0.001),高表达C-fos的NPC对紫杉醇的耐药率显著高于低表达组(P=0.036),其余7种化疗药物组间耐药率均差异无统计学意义;高表达C-fos的NPC患者肿瘤进展率显著高于低表达组(P=0.014),死亡率差异无统计学意义(P=0.148);高表达C-fos的NPC患者无进展生存率显著差于低表达组(P=0.008),总生存率差异无统计学意义(P=0.076)。结论: C-fos高表达于NPC组织,并且NPC组织中C-fos高表达可能与肿瘤进展及对紫杉醇的耐药相关。
- 鼻咽癌 /
- C-fos /
- 化疗敏感性 /
- 预后
Abstract: Objective: To investigate the expression of C-fos in patients with nasopharyngeal carcinoma(NPC), and analyze the relationship between the expression of C-fos and the clinical characteristics, chemosensitivity and prognosis.Method: Clinical and follow-up data of 75 NPC patients was analyzed retrospectively. The expression of C-fos was detected by immunohistochemical assay, and chemosensitivity was detected by ATP bioluminescent anticancer drug sensitivity detection technology. The relationship between them was studied.Result: The expression of C-fos in NPC was statistically higher than that in the control nasopharyngeal mucosa(P<0.001). It was found that C-fos had no statistical relationship with the gender, age, pathologic type, clinical stage of tumor classification, lymph node status, metastasis status and overall stage of NPC patients(P>0.05). NPC had different chemosensitivity with 8 anticancer drugs(P<0.001).There was a significant difference in chemosensitivity of paclitaxel between the high expression of C-fos group and the low expression of C-fos group(P=0.036). The rate of tumor progression was significantly higher in NPC patients with high expression of C-fos than in the low expression group(P=0.014).There was no significant difference in overall survival between the two groups(P=0.076).Conclusion: C-fos is highly expressed in NPC tissues, and the high expression of C-fos in NPC tissues may be related to tumor progression and resistance to paclitaxel.
- nasopharyngeal carcinoma /
- C-fos /
- chemosensitivity /
- prognosis

HTML全文

参考文献(25)

[1]	PARKIN D M, BRAY F, FERLAY J.Global cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55:74-108.
[2]	CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66:115-132.
[3]	MAO Y P, XIE F Y, LIU L Z, et al.Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging[J].Int J Radiat Oncol Biol Phys, 2009, 73:1326-1334.
[4]	ZHANG L F, LI Y H, XIE S H, et al.Incidence trend of nasopharyngeal carcinoma from 1987to 2011in Sihui County, Guangdong Province, South China:an ageperiod-cohort analysis[J].Chin J Cancer, 2015, 34:350-357.
[5]	LEE A W, NG W T, CHAN L K, et al.The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement[J].Oral Oncol, 2012, 48:1007-1013.
[6]	CHEN L, MAO Y P, XIE F Y, et al.The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China[J].Radiother Oncol, 2012, 104:331-337.
[7]	MILDE-LANGOSCH K.The Fos family of transcription factors and their role in tumourigenesis[J].Eur J Cancer, 2005, 41:2449-2461.
[8]	SHI R, PENG H, YUAN X, et al.Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation[J].J Cell Biochem, 2013, 114:1890-1900.
[9]	KURBACHER C M, CREE I A, BRUCKNER H W.Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer[J].Anticancer Drugs, 1998, 9:51-57.
[10]	LIU Z G, JIANG G, TANG J, et al.c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma[J].Oncotarget, 2016, 7:65946-65956.
[11]	BAI L, MAO R, WANG J, et al.ERK1/2promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins[J].Med Oncol, 2015, 32:57-61.
[12]	VOLM M, DRINGS P.Prognostic significance of the expression of c-fos, c-jun and c-erbB-1oncogene products in human squamous cell lung carcinomas[J].J Cancer Res Clin Oncol, 1993, 119:507-510.
[13]	PANDEY M K, LIU G, COOPER T K.Knockdown of c-Fos suppresses the growth of human colon carcinoma cells in athymic mice[J].Int J Cancer, 2012, 130:213-222.
[14]	LAN G, YANG L, XIE X, et al.MicroRNA-490-5p is a novel tumor suppress or targeting c-FOS in human bladder cancer[J].Arch Med Sci, 2015, 11:561-569.
[15]	FAN Q, HE M, DENG X, et al.Derepression of c-Fos caused by microRNA-139down-regulation contributes to the metastasis of human hepatocellular carcinoma[J].Cell Biochem Funct, 2013, 31:319-324.
[16]	DONG C, YE D X, ZHANG W B, et al.Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma[J].J Oral Pathol Med, 2015, 44:353-360.
[17]	王树森, 管忠震, 向燕群, 等.鼻咽癌组织中c-Fos和Cyclin D1蛋白表达的检测及意义[J].中国肿瘤临床, 2005, 19 (6):341-343.
[18]	BAUJAT B, AUDRY H, BOURHIS J, et al.Chemotherapy in locally advanced nasopharyngeal carcinoma:an individual patient data meta-analysis of eight randomized trials and 1753patients[J].Int J Radiat Oncol Biol Phys, 2006, 64:47-56.
[19]	吴峰, 吴立连, 陈国富, 等.不同化疗方案同步调强放疗治疗Ⅲ-Ⅳa期鼻咽癌疗效的回顾性分析[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (19):1536-1539.
[20]	王洪波, 陈燕.诱导化疗与同期化疗对局部晚期鼻咽癌患者远期疗效的对比研究[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (5):361-365.
[21]	ZHANG L, HUANG Y, HONG S, et al.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre, randomised, open-label, phase 3trial[J].Lancet, 2016, 388:1883-1892.
[22]	BUTTRICK G J.PI3-K and GSK-3:Akt-ing together with microtubules[J].Cell Cycle, 2008, 7:2621-2625.
[23]	SINGLA A K, GARG A.Paclitaxel and its formulations[J].Int J Pharm, 2002, 235:179-192.
[24]	CHEN D, LIN X, ZHANG C, et al.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway[J].Cell Death Dis, 2018, 9:123-127.
[25]	MUHAMMAD N, BHATTACHARYA S, STEELE R, et al.Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma[J].Clin Cancer Res, 2017, 23:3120-3128.